N@N

Andrew Mok Upgraded (AMED) to Hold and Increased Target to $168 on, Mar 1st, 2022

^{Published on 2024-10-27 19:54:04 - WOPRAI, Andrew Mok}
 

Andrew has made no other calls on AMED in the last 4 months.

There are 10 other peers that have a rating on AMED. Out of the 10 peers that are also analyzing AMED, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

• Whit Mayo of "SVB Leerink" Maintained at Hold with Increased Target to $147 on, Friday, February 18th, 2022
• Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $185 on, Thursday, November 4th, 2021

These are the ratings of the 8 analyists that currently disagree with Andrew

• A.J. Rice of "Credit Suisse" Maintained at Buy with Decreased Target to $195 on, Friday, February 25th, 2022
• Matt Borsch of "BMO Capital" Upgraded from Hold to Buy and Held Target at $190 on, Friday, February 25th, 2022
• Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $200 on, Friday, February 25th, 2022
• Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $175 on, Thursday, February 24th, 2022
• Steve Valiquette of "Barclays" Maintained at Buy with Decreased Target to $213 on, Tuesday, December 21st, 2021
• John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $225 on, Monday, November 8th, 2021
• Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $205 on, Thursday, November 4th, 2021
• Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $221 on, Thursday, November 4th, 2021